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S U M M A R Y
Objective: To assess high-risk human papillomavirus (HR HPV) cervical infections and their type
distribution among healthy women in Guadeloupe, French West Indies.
Methods: The details of consecutive non-pregnant women who attended cervical cancer screening and
had HPV genotyping performed at the largest pathology laboratory on the island from January 1, 2013 to
December 31, 2014 were recorded retrospectively. All women with available HPV genotyping results
were included in the study.
Results: HR HPV genotyping results for 618 women (median age 42 years) were collected. The overall
prevalence rate of HR HPV cervical infection was 36.1% (95% conﬁdence interval (CI) 32.3–40.0%), with
the following type distribution: HPV 16 or 18 irrespective of other HPV types, 7.3% (95% CI 5.4–9.6%);
other HR HPV types excluding HPV 16 or 18, 28.8% (95% CI 25.3–32.5%). The prevalence rates of overall
HR HPV and HR HPV other than 16 or 18 infection increased signiﬁcantly (p < 0.001) with the severity of
cytology grade, from 19.7% for normal cytology to 53.8% in atypical squamous cells of undetermined
signiﬁcance (ASC-US) and 67.7% in low-grade squamous intraepithelial lesions (LSIL).
Conclusion: The high prevalence rate of HR HPV cervical infection with genotypes other than 16 and
18 in Guadeloupe, irrespective of age and the cytology grade, suggests a potential beneﬁt of the new
nine-valent HPV vaccine to prevent HPV infection-related cancers in this Caribbean country.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Virus-related cancers are a leading cause of death in Caribbean
countries,1,2 and have been identiﬁed as an important public
health problem by the French West Indies cancer registries. The
most common of these viruses associated with cancer are the
human papillomavirus (HPV) types designated as ‘high risk’ (HR);
these are implicated in 99% of cervical cancer, in 40–80% of
anogenital cancers other than cervical, and in approximately 25%
of head and neck cancers.3–9 The most prevalent HR HPV types in§ Nade`ge Cordel and Camille Ragin are members of the African Caribbean Cancer
Consortium..
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).invasive cervical cancers worldwide are types 16 and 18, which are
the primary targets of current HPV vaccination programs.10–12
Although the prevalence of HPV infection and incidence rates of
cervical cancer are high in the Caribbean, limited data are available
on the prevalence of HR HPV cervical infections among healthy
Caribbean women.1,2,10,13–17 In addition, very few studies have
been performed to describe the HR HPV type distribution in this
population. Investigators of the African Caribbean Cancer Consor-
tium have reported a high prevalence rate of HPV 45 rather than
HPV 16 or 18 in Tobago, Jamaica, and Barbados.14–16 No data are
available for the French West Indies. The recent US Food and Drug
Administration (FDA) approval of a second-generation HPV
vaccine that targets ﬁve HR HPV types (i.e., 31, 33, 45, 52, and
58) in addition to 16 and 18 warrants the evaluation of HR HPV
cervical infections in the whole Caribbean.18 This new prophylacticciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
N. Cordel et al. / International Journal of Infectious Diseases 41 (2015) 13–1614vaccine may be more appropriate in Caribbean vaccination
programs for the prevention of cervical cancer.10,19
Guadeloupe, an overseas department of France, is the largest
island of the French West Indies (405 000 inhabitants, mostly Black
Caribbean persons of African and European descent). A retrospec-
tive study was conducted on the island of Guadeloupe in order to
assess the prevalence of cervical HR HPV infections and the type
distribution of HR HPV among healthy women in this Caribbean
country.
2. Patients and methods
2.1. Data and sample collection
The details of consecutive non-pregnant women who attended
cervical cancer screening and had HPV genotyping performed at
the largest pathology laboratory on the island from January 1,
2013 to December 31, 2014 were recorded. All cases with available
HPV genotyping results of liquid-based cytology samples were
included in the study.
Pathology charts were reviewed retrospectively using the
computerized database of the laboratory and DIAMIC software.
The following data were recorded: resident status to conﬁrm
permanent residence on the island of Guadeloupe during the study
period, date of birth, date of sampling, and cytology results
according to the Bethesda System 2001.20 Samples were classiﬁed
as atypical squamous cells of undetermined signiﬁcance (ASC-US),
low-grade squamous intraepithelial lesion (LSIL), or high-grade
squamous intraepithelial lesion (HSIL).
2.2. HPV testing and genotyping
The genotyping analysis of liquid-based cytology specimens
collected in PreservCyt (Hologic Corp.) was performed indepen-
dently from the histopathological examination, using a semi-
genotyping kit (Cobas 4800 HPV test, Roche Diagnostics). This
qualitative multiplex assay provides speciﬁc genotyping of HPV
16 and 18 while concurrently detecting the other HR HPV types
(i.e., 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in a pooled
analysis using ampliﬁcation of the target DNA by PCR and nucleic
acid hybridization.
2.3. Statistical analysis
Results were recorded as numbers and frequencies. The
prevalence rates of HPV infection were calculated with 95%
conﬁdence intervals (CIs). Age was described using the median and
interquartile range (Q1–Q3). Stratiﬁcation according to age was
performed to analyze the HR HPV type distribution by cytology
grade within each age group: 18–24, 25–29, 30–39, 40–49, 50–64,
and 65 years. Cross-tabulations were analyzed by Chi-square test
or Fisher’s exact test when appropriate. Comparisons of prevalence
rates with other countries were based on the Chi-square test.Table 1
Prevalence of HR HPV cervical infections by cytology grade
Cytology grade
Normal (n = 447) ASC
n % 95% CI n 
Overall HR HPV 112 25.1 21.1–29.3 69 
HR HPV 16 and/or 18 irrespective
of other HR HPV types
24 5.4 3.5–7.9 12 
Other HR HPV excluding 16 and 18 88 19.7 16.1–23.7 57 
HR, high-risk; HPV, human papillomavirus; ASC-US, atypical squamous cell of undeterm
interval.For all analyses, two-sided p-values of less than 0.05 were
considered statistically signiﬁcant. Data management and the
statistical analysis were performed using SPSS v.17.0 software
(SPSS Inc., Chicago, IL, USA).
2.4. Ethical considerations
This retrospective study was approved by the Ethics Committee
for Non-interventional Research of Rouen University Hospital
(registered number E2015-37).
3. Results
A total of 618 consecutive HR HPV genotyping results from
618 women were collected. The median age of the study
population was 42 years (Q1–Q3 32–52 years). The overall
prevalence rate of HR HPV cervical infection was 36.1% (95% CI
32.3–40.0%). The distribution of HR HPV types was as follows: HPV
16 or 18 irrespective of other HPV types, 7.3% (95% CI 5.4–9.6%);
other HR HPV types excluding HPV 16 and 18, 28.8% (95% CI 25.3–
32.5%).
Cytology results were available for 592 of the 618 cases and
were classiﬁed as normal for 447 women, ASC-US for 106 women,
LSIL for 31 women, and HSIL for eight women.
Interestingly, the overall prevalence rate of HR HPV cervical
infection increased signiﬁcantly (p < 0.001) with the severity of
cytology grade from normal to LSIL, as did the prevalence rate of HR
HPV other than 16 or 18 infection. These varied from 25.1% (95% CI
21.1–29.3%) and 19.7% (95% CI 16.1–23.7%) for normal cytology to
65.1% (95% CI 55.2–74.1%) and 53.8% (95% CI43.8–53.5%) in ASC-US
and 77.4% (95% CI 58.9–90.4%) and 67.7% (95% CI 48.6–83.3%) in
LSIL (Table 1). The HSIL group was not considered for the analysis
because of its small size (n = 8).
Table 2 shows the HR HPV type distribution by country (i.e.,
Guadeloupe, France, developed regions, and Tobago) for normal
cytology; data were obtained from Heard et al.,21 the World Health
Organization/Institut Catala` d’Oncologia (WHO/ICO) 2010 report,10
and a secondary analysis of data published previously from the
Tobago study performed by Ragin et al.14 The overall prevalence
rate of cervical HR HPV infection, as well as the prevalence rate of
HR HPV other than 16 or 18 infection, was signiﬁcantly higher in
Guadeloupe than in France and in developed regions (p < 0.001).
Conversely, the crude prevalence of HPV 16 and/or 18 cervical
infection was not signiﬁcantly different between Guadeloupe and
other countries. Interestingly, data from the Caribbean island of
Tobago were of the same order of magnitude as those recorded in
Guadeloupe.
Figure 1 presents the crude prevalence of overall HR HPV, HPV
16 and/or 18, and HR HPV other than 16 or 18 cervical infections by
grade of cytology for each age group. Regardless of the cytology
grade, the overall rate of HR HPV cervical infection decreased with
age for women older than 29 years, except for the age group 65
years. The largest drop was observed in ASC-US for women aged-US (n = 106) LSIL (n = 31) p-Value
% 95% CI n % 95% CI
65.1 55.2–74.1 24 77.4 58.9–90.4 <0.001
11.3 6.0–18.9 3 9.7 2.0–25.8 0.060
53.8 43.8–63.5 21 67.7 48.6–83.3 <0.001
ined signiﬁcance; LSIL, low-grade squamous intraepithelial lesion; CI, conﬁdence
Table 2
HR HPV type distribution by country for normal cytology
Guadeloupe
(French West
Indies)
France
(Heard et al., 2013)
Developed regions
(WHO/ICO 2010)
Tobago
(Ragin et al., 2007)
% 95% CI % 95% CI p-Valuea % 95% CI p-Valuea % 95% CI p-Valuea
HR HPVb 25.1 21.1–29.3 13.7 11.7–15.6 <0.001 10.3 10.2–10.4 <0.001 20.6 15.3–26.8 0.192
HPV 16 and/or 18c 5.4 3.5–7.9 3.9 2.8–5.1 0.089 3.6 3.5–3.7 0.017 2.5 0.8–5.6 0.089
HR HPV other than
16 and/or 18d
19.7 16.1–23.7 9.7 8.0–11.4 <0.001 6.0 5.9–6.1 <0.001 18.1 13.1–24.1 0.616
HR, high-risk; HPV, human papillomavirus; WHO/ICO, World Health Organization/Institut Catala` d’Oncologia; CI, conﬁdence interval.
a Comparison to Guadeloupe.
b At least one HR HPV type among 16, 18, and other HR types (i.e., 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
c HPV 16 and/or 18 irrespective of other HR HPV types.
d Other HR HPV types, excluding HPV 16 and 18.
N. Cordel et al. / International Journal of Infectious Diseases 41 (2015) 13–16 1550–64 years (i.e., overall HR HPV of 25% (95% CI 8.7–49.1), HPV
16 and/or 18 of 10% (95% CI 1.2–31.7), HR HPV other than 16 or
18 of 15% (95% CI 3.2–37.9) versus 74% (p < 0.001), 12% and 62%
(p < 0.001), respectively, for younger women). Interestingly,
whatever the age group, the cervical infection rate of HR HPV
other than 16 or 18 was always higher than the corresponding rate
of HPV 16 and/or 18 infection for each cytology grade from normal
to LSIL. This was particularly obvious for the latter cytology grade,
for which the rate of HPV 16 and/or 18 cervical infection was 0% in
all age groups except for women aged 30–39 years (i.e., 27.3%).
4. Discussion
This study is the ﬁrst report of HR HPV cervical infection among
healthy women from the general population of the French West
Indies. Moreover this is the ﬁrst study describing the HR HPV
distribution type among age groups and cervical cytology grades in
healthy Caribbean women.
A high overall HR HPV cervical infection crude prevalence of
36.1% (95% CI 32.3–40.0) was demonstrated. This high prevalence
rate is in accordance with those of all previous Caribbean studies,
in which the crude prevalence of HR HPV cervical infection has
varied between 35.4% in Tobago2,14 and 70.8% in Jamaica.15
As in previous worldwide studies and in the largest French
study, it was found that the crude prevalence of HR HPV cervical
infection was highest in young women, decreasing in women of
older age,10,21,22 but increasing slightly in women 65 years of age
compared to women aged 50–64 years.21
The main result of this study is the very high prevalence rate of
HR HPV infection with genotypes other than 16 and 18 in
Guadeloupe, irrespective of age and the cytology grade from
normal to LSIL. The higher prevalence rate of infections caused by0.0%
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Figure 1. Crude prevalence of overall HR HPV, HPV 16 and/or 18, and HR HPV othHR HPV types other than 16 or 18 compared to the rate for HPV
16 and/or 18 has been highlighted in previous studies from
developed regions,10,22 as well as in the large French series
published by Heard et al.,21 but this was not of the same order of
magnitude as in the present study. Indeed, in the present study, the
crude prevalence of HR HPV cervical infections with genotypes
other than 16 or 18 was found to vary from 19.7% (95% CI 16.1–
23.7%) for normal cytology to 53.8% (95% CI 43.8–53.5%) in ASC-US
and 67.7% (95% CI 48.6–83.3%) in LSIL. These results are in
accordance with those of a previous study in Tobago, which
demonstrated a crude prevalence rate of 18.1% (95% CI 13.1–24.1%)
for infection with HR HPV types other than 16 or 18 versus 2.5% for
infection with HPV 16 and/or 18 in healthy women with normal
cytology (Table 2).14
The recent worldwide study by Serrano et al., including
10 575 invasive cervical cancer cases from 48 countries except
the Caribbean, was performed in order to estimate the relative
contribution of the nine HPV types targeted in the second-
generation HPV vaccine; this study conﬁrmed the variation in
relative contribution of HPV 16/18 among geographical regions.19
Thus the recently FDA-approved nine-valent HPV vaccine, which
covers ﬁve additional HR HPV types (i.e., 31, 33, 45, 52, and 58) to
those covered by current HPV vaccines, could help to increase
protection against HPV infection-related cancers, particularly in
regions with high prevalence rates of HR HPV cervical infection
with genotypes other than 16 or 18, such as the Caribbean. This is
supported by the recent report on 131 invasive cervical cancers
from Martinique (French West Indies), which showed a slightly
heterogeneous distribution of HR HPV types: HPV 16 (47%), HPV 35
(14%), HPV 18 (10%), HPV 33 (8%), HPV 45 (6%), and HPV 51 (6%).23
As with all retrospective studies, this study has various possible
biases. To limit the selection bias due to the single-center design,0-
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er than 16 or 18 cervical infections by grade of cytology for each age group.
N. Cordel et al. / International Journal of Infectious Diseases 41 (2015) 13–1616all consecutive HPV genotyping results registered in the largest
pathology laboratory of Guadeloupe, which handles more than
10 000 Pap smears per year from women living in all parts of the
island, were included exhaustively. The absence of major selection
bias in this series is supported by the similarities in clinical features
(i.e., median age 42 years) and in the crude prevalence of overall HR
HPV, HR HPV other than 16 or 18, and HPV 16 or 18 infection in this
series compared to those found in previous Caribbean studies.14–16
In conclusion, the present study showed a high prevalence rate
of HR HPV cervical infection of 36.1% in healthy women from
Guadeloupe, attributable to a high rate of infection with HR HPV
genotypes other than 16 or 18 (i.e., 28.8%). These ﬁndings suggest
that larger Caribbean studies should be performed in order to
assess the potential impact of the new HPV vaccine on the
Caribbean HPV ecology and related cervical lesions. This second-
generation HPV vaccine might potentially be helpful in the
development of an appropriate Caribbean vaccination program
for the prevention of cervical cancer, which is a current public
health problem in this region.
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